{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:27Z","timestamp":1793060067354,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Little is known about the relationship between the disease activity of Beh\u00e7et disease (BD) and the incidence of inflammatory major organ events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In this prospective registry study, we investigated the association between the Beh\u00e7et Disease Current Activity Form (BDCAF) and incidence of inflammatory major organ events, defined as the inflammation of the ocular, central nervous, intestinal, and vascular systems in BD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled participants from Japanese multicenter prospective cohorts. The BDCAF was evaluated annually. BD-related symptoms, including inflammatory major organ events, were monitored. The association between BDCAF and inflammatory major organ events was analyzed by time-to-event analysis. An unsupervised clustering of the participants\u2019 BDCAF, therapeutic agents, and multiple serum cytokines was also performed to examine their association with inflammatory major organ events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 260 patients were included. The patients had a median BDCAF score of 2 [Interquartile range, 1-3] at the enrolment and remained disease active at 1- and 2-year follow-ups, indicating residual disease activity in BD. Patients with a BDCAF score of 0 had a longer inflammatory major organ event-free survival at 52 weeks than those with a score of 1 or higher (p=2.2 x 10<jats:sup>-4<\/jats:sup>). Clustering analysis revealed that patients who did not achieve remission despite treatment with tumor necrosis factor inhibitors had high serum inflammatory cytokine levels and incidences of inflammatory major organ events. Among the elevated cytokines, IL-6 was associated with inflammatory major organ events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests that treatment strategies targeting overall disease activity and monitoring residual serum IL-6 may help prevent inflammatory major organ events in BD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1354969","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:07:03Z","timestamp":1713186423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Beh\u00e7et disease: a prospective registry study"],"prefix":"10.3389","volume":"15","author":[{"given":"Lisa","family":"Hirahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Fujieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrrheum.2018.3","article-title":"Behcet syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.6.783","article-title":"Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Behcet\u2019s syndrome","volume":"43","author":"Yazici","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-006-0541-z","article-title":"HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet\u2019s disease","volume":"17","author":"Aramaki","year":"2007","journal-title":"Mod Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Behcet disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000373","article-title":"Surgical treatment and outcomes in patients with intestinal behcet disease: long-term experience of a single large-volume center","volume":"58","author":"Baek","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1641611","article-title":"The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular behcet\u2019s disease patients","volume":"28","author":"Shirahama","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0533-5","article-title":"Clinical characteristics of neuro-Behcet\u2019s disease in Japan: a multicenter retrospective analysis","volume":"22","author":"Hirohata","year":"2012","journal-title":"Mod Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jgh.13530","article-title":"Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behcet\u2019s disease","volume":"32","author":"Kim","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa264","article-title":"Femoral vein wall thickness measurement: A new diagnostic tool for Behcet\u2019s disease","volume":"60","author":"Alibaz-Oner","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","article-title":"A treat-to-target approach is needed for Behcet\u2019s syndrome","volume":"34","author":"Hatemi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216819","article-title":"Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24511","article-title":"Core set of domains for outcome measures in behcet\u2019s syndrome","volume":"74","author":"Hatemi","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg453","article-title":"The Behcet\u2019s disease activity index","volume":"43","author":"Lawton","year":"2004","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3899\/jrheum.131249","article-title":"Outcome measures used in clinical trials for Beh\u00e7et syndrome: a systematic review","volume":"41","author":"Hatemi","year":"2014","journal-title":"J Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in behcet\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001192","article-title":"Development and preliminary validation of the Beh\u00e7et\u2019s syndrome Overall Damage Index (BODI)","volume":"6","author":"Piga","year":"2020","journal-title":"RMD Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13075-022-02947-y","article-title":"Accrual of organ damage in Behcet\u2019s syndrome: trajectory, associated factors, and impact on patients\u2019 quality of life over a 2-year prospective follow-up study","volume":"24","author":"Floris","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B20","first-page":"8","volume-title":"Guide for the diagnosis of Beh\u00e7et\u2019s disease. Report of Beh\u00e7et\u2019s Disease Research Committee","author":"Mizushima Y","year":"1987"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev202","article-title":"High mobility group box 1 serum levels are increased in Beh\u00e7et\u2019s disease, but not associated with disease activity or disease manifestations","volume":"54","author":"de Souza","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13072","article-title":"Increased serum interleukin-32 levels in patients with Beh\u00e7et\u2019s disease","volume":"21","author":"Ha","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5152\/eurjrheum.2020.20010","article-title":"Use of prognostic nutritional index in the evaluation of disease activity in patients with Beh\u00e7et\u2019s disease","volume":"7","author":"Ata\u015f","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B27","article-title":"Adalimumab for treatment of severe Beh\u00e7et\u2019s uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B28","volume-title":"Classification and Regression Trees","author":"Breiman","year":"1984"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.05.014","article-title":"Genome-wide association study in asians identifies novel loci for high myopia and highlights a nervous system role in its pathogenesis","volume":"127","author":"Meguro","year":"2020","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2520","article-title":"Genome-wide association analysis identifies new susceptibility loci for Behcet\u2019s disease and epistasis between HLA-B*51 and ERAP1","volume":"45","author":"Kirino","year":"2013","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209059","article-title":"A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behcet\u2019s disease in HLA-B*51 carriers","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.624","article-title":"Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet\u2019s disease susceptibility loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01896809","article-title":"Metric and Euclidean properties of dissimilarity coefficients","volume":"3","author":"Gower","year":"1986","journal-title":"J Classification"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1007\/0-387-29362-0_23","article-title":"Limma: linear models for microarray data","volume-title":"Bioinformatics and computational biology solutions using R and Bioconductor","author":"Smyth","year":"2005"},{"key":"B35","volume-title":"Package \u2018survivalROC\u2019","author":"Heagerty","year":"2013"},{"key":"B36","unstructured":"survRM2: Comparing Restricted Mean Survival Time. R package version 1.0-4\n            UnoH\n            TianL\n            HoriguchiM\n            CroninA\n            BattiouiC\n            BellJ\n          2022"},{"key":"B37","unstructured":"Package \u2018rpart\u2019\n            TherneauT\n            AtkinsonB\n            RipleyB\n            RipleyMB\n          2015"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"B40","unstructured":"cluster: Cluster Analysis Basics and Extensions. R package version 2.1.6 \u2014 For new features, see the \u2018NEWS\u2019 and the \u2018Changelog\u2019 file in the package source)\n            MaechlerM\n            RousseeuwP\n            StruyfA\n            HubertM\n            HornikK\n          2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v074.i07","article-title":"Imputation with the R package VIM","volume":"74","author":"Kowarik","year":"2016","journal-title":"J Stat Software"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713052","article-title":"Pathogenesis of beh\u00e7et\u2019s syndrome: genetic, environmental and immunological factors","volume":"8","author":"Mattioli","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1306352110","article-title":"Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease","volume":"110","author":"Kirino","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.12.1.53.28062","article-title":"The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh\u00e7et\u2019s disease with ocular involvement","volume":"12","author":"Bardak","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"B45","first-page":"6","article-title":"Serum IL-33 levels and skin mRNA expression in Beh\u00e7et\u2019s disease","volume":"31","author":"Hamzaoui","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.4268","article-title":"Cerebrospinal fluid interleukin-6 in progressive Neuro-Beh\u00e7et\u2019s syndrome","volume":"82","author":"Hirohata","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et\u2019s disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet\u2019s disease: A systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/avhxp6","article-title":"IL-6 blockade for Beh\u00e7et\u2019s disease: review on 31 anti-TNF naive and 45 anti-TNF experienced patients","volume":"40","author":"Arida","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356corr1","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B53","first-page":"77","article-title":"Patient-driven assessment of disease activity in Behcet\u2019s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behcet\u2019s Syndrome Activity Score","volume":"31","author":"Yilmaz","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1354969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T13:07:11Z","timestamp":1713186431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1354969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2024.1354969"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1354969","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1354969"}}